Anti-CD47 antibody-decorated and cisplatin-containing mesoporous silica nanoparticles for targeted chemoimmunotherapy of colorectal cancer in a patient-derived organoids xenograft model

Abstract

For colorectal cancer (CRC), treatment outcomes and prognosis remain poor even when using first-line chemotherapeutics and immunotherapeutics. The main reasons include (i) lack of tumor specificity, severe off-target cytotoxicity leading to adverse side effects, and occurrence of chemoresistance, and (ii) the immunosuppressive “cold” tumor microenvironment (TME). Herein, we demonstrate an example of highly efficient targeted CRC chemoimmunotherapy with cisplatin (CDDP)-containing nanomedicine (CDDP@MSN-Anti-CD47) in a patient-derived organoids xenograft model. The CDDP@MSN-Anti-CD47 is composed of CDDP-loaded mesoporous silica nanoparticles with superficially functionalized anti-CD47 antibodies to target cluster of differentiation CD47, a transmembrane integrin-associated protein that is over-expressed in CRC cells and can bind with signal regulatory protein α on tumor-associated macrophages (TAMs) to maintain the immunosuppressive TME. Our results demonstrated that CDDP@MSN-Anti-CD47 achieved targeted delivery of CDDP to CRC cells with extended release, and induced reactive oxygen species overproduction to inhibit CRC cells and CRC patient-derived organoids growth via activating caspase-3-related apoptosis and immunogenic cell death. DAMPs released following CDDP@MSN-Anti-CD47 treatment promoted the polarization of TAMs from immunosuppressive M2 to pro-inflammatory M1 phenotype and also synergized with the functionalized anti-CD47 antibodies to restore macrophage phagocytic activity against CRC cells. In both CRC cell and patient-derived organoid xenograft models, CDDP@MSN-Anti-CD47 could specifically target the tumor, showing strong anti-tumor effects, prolonged survival rate, and low systemic cytotoxicity. Overall, CDDP@MSN-Anti augments combination chemotherapy and immunotherapy, and can be developed as a novel and promising strategy for the clinical treatment of CRC.

Keywords

cisplatin extended release / colorectal cancer / CRC-derived organoids / mesoporous silica nanoparticles / synergistic chemotherapeutic immunotherapy / tumor-associated macrophages

References

[1] R. L. Siegel, A. N. Giaquinto, A. Jemal, CA - Cancer J. Clin. 2024, 74, 12.

[2] E. Morgan, M. Arnold, A. Gini, V. Lorenzoni, C. J. Cabasag, M. Laversanne, J. Vignat, J. Ferlay, N. Murphy, F. Bray, Gut 2023, 72, 338.

[3] A. Cañellas-Socias, E. Sancho, E. Batlle, Nat. Rev. Gastroenterol. Hepatol. 2024, 21, 609.

[4] A. Cervantes, R. Adam, S. Roselló, D. Arnold, N. Normanno, J. Taïeb, J. Seligmann, T. De Baere, P. Osterlund, T. Yoshino, E. Martinelli, Ann. Oncol. 2023, 34, 10.

[5] L. H. Biller, D. Schrag, JAMA, J. Am. Med. Assoc. 2021, 325, 669.

[6] C. Zhang, C. Xu, X. Gao, Q. Yao, Theranostics 2022, 12, 2115.

[7] C. Tang, M. J. Livingston, R. Safirstein, Z. Dong, Nat. Rev. Nephrol. 2023, 19, 53.

[8] E. V. Sazonova, G. S. Kopeina, E. N. Imyanitov, B. Zhivotovsky, Cell Death Discov. 2021, 7, 155.

[9] D. Salas-Benito, J. L. Pérez-Gracia, M. Ponz-Sarvisé, M. E. Rodriguez-Ruiz, I. Martínez-Forero, E. Castañón, J. M. López-Picazo, M. F. Sanmamed, I. Melero, Cancer Discov. 2021, 11, 1353.

[10] T. Sha, Y. Tang, X. Hu, H. Zhou, L. Rao, Interdiscip. Med. 2025, 3, e20240103.

[11] S. W. Linderman, L. DeRidder, L. Sanjurjo, M. B. Foote, M. J. Alonso, A. R. Kirtane, R. Langer, G. Traverso, Nat. Rev. Clin. Oncol. 2025, 22, 262.

[12] S. Goswami, K. E. Pauken, L. Wang, P. Sharma, Nat. Immunol. 2024, 25, 2186.

[13] H. Kikuchi, N. Maishi, L. Yu, Z. Jia, C. Li, M. Sato, R. Takeda, K. Ishizuka, Y. Hida, N. Shinohara, K. Hida, Br. J. Cancer 2024, 130, 336.

[14] M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, R. Langer, Nat. Rev. Drug Discov. 2021, 20, 101.

[15] X. Wang, K. Mao, X. Zhang, Y. Zhang, Y. G. Yang, T. Sun, Interdiscip. Med. 2024, 2, e20240014.

[16] M. Vallet-Regí, F. Schüth, D. Lozano, M. Colilla, M. Manzano, Chem. Soc. Rev. 2022, 51, 5365.

[17] B. Xu, S. Li, R. Shi, H. Liu, Signal Transduct. Target. Ther. 2023, 8, 435.

[18] R. Jin, L. Neufeld, T. L. McGaha, Nat. Cancer 2025, 6, 239.

[19] J. Li, L. Xiang, S. Wang, Y. Zhang, S. Zhao, D. Zhang, X. Meng, Y. Zhang, J. M. Lin, Interdiscip. Med. 2025, 3, e20240069.

[20] C. Zhang, C. Zhang, H. Wang, Cancer Lett. 2023, 562, 216182.

[21] K. Yu, B. Chen, D. Aran, J. Charalel, C. Yau, D. M. Wolf, L. J. van ‘t Veer, A. J. Butte, T. Goldstein, M. Sirota, Nat. Commun. 2019, 10, 3574.

[22] M. M. A. Verstegen, R. P. Coppes, A. Beghin, P. De Coppi, M. F. M. Gerli, N. de Graeff, Q. Pan, Y. Saito, S. Shi, A. A. Zadpoor, L. J. W. van der Laan, Nat. Med. 2025, 31, 409.

[23] R. Tang, X. Q. Liu, Interdiscip. Med. 2025, 3, e20240083.

[24] R. Polak, E. T. Zhang, C. J. Kuo, Nat. Rev. Cancer 2024, 24, 523.

[25] B. L. LeSavage, R. A. Suhar, N. Broguiere, M. P. Lutolf, S. C. Heilshorn, Nat. Mater. 2022, 21, 143.

[26] Z. Hussain, S. Gou, X. Liu, M. Li, H. Zhang, S. Ren, R. Han, F. Liu, X. Zhou, L. Qiu, H. Wang, Z. Chen, K. Liu, Mater. Today Bio 2025, 32, 101826.

[27] J. Q. Luo, R. Liu, F. M. Chen, J. Y. Zhang, S. J. Zheng, D. Shao, J. Z. Du, ACS Nano 2023, 17, 8966.

[28] S. Ma, W. Wang, J. Zhou, S. Liao, C. Hai, Y. Hou, Z. Zhou, Z. Wang, Y. Su, Y. Zhu, X. Dai, Y. Zhao, S. Liao, Y. Cai, X. Xu, Proc. Natl. Acad. Sci. USA 2024, 121, e2408939121.

[29] H. Fang, X. Wang, X. Lan, D. Jiang, Interdiscip. Med. 2023, 1, e20230002.

[30] Y. Choi, M. J. Jeon, W. K. L. Doolittle, D. E. Song, K. Kim, W. B. Kim, W. G. Kim, Thyroid 2024, 34, 1150.

[31] B. Yang, Y. Zhao, W. Luo, W. Zhu, L. Jin, M. Wang, L. Ye, Y. Wang, G. Liang, Cell Death Dis. 2023, 14, 419.

[32] Y.-W. Hu, F.-X. Guo, Y.-J. Xu, P. Li, Z.-F. Lu, D. G. McVey, L. Zheng, Q. Wang, J. H. Ye, C.-M. Kang, S.-G. Wu, J.-J. Zhao, X. Ma, Z. Yang, F.-C. Fang, Y.-R. Qiu, B.-M. Xu, L. Xiao, Q. Wu, L.-M. Wu, L. Ding, T. R. Webb, N. J. Samani, S. Ye, J. Clin. Invest. 2019, 129, 1115.

[33] M. Talmon, L. Camillo, I. Vietti, F. Pollastro, L. G. Fresu, Int. J. Mol. Sci. 2024, 25, 7325.

[34] S. Omer, J. Li, C. X. Yang, R. E. Harrison, Mol. Biol. Cell 2024, 35, ar26.

[35] H. Atcha, A. Jairaman, J. R. Holt, V. S. Meli, R. R. Nagalla, P. K. Veerasubramanian, K. T. Brumm, H. E. Lim, S. Othy, M. D. Cahalan, M. M. Pathak, W. F. Liu, Nat. Commun. 2021, 12, 3256.

[36] X. Wang, A. Iyer, A. B. Lyons, H. Körner, W. Wei, Front. Immunol. 2019, 10, 2031.

[37] L. Ji, F. Xu, J. Zhang, T. Song, W. Chen, X. Yin, Q. Wang, X. Chen, X. Li, M. Guo, Z. Chen, Sci. Rep. 2022, 12, 15994.

[38] H. Huang, Y. Chen, N. Yin, G. Li, S. Ye, L. Guo, M. Feng, Mol. Pharm. 2023, 20, 290.

[39] S. Maccari, E. Profumo, L. Saso, G. Marano, B. Buttari, Int. J. Mol. Sci. 2024, 25, 3683.

[40] N. Wang, S. Wang, X. Wang, Y. Zheng, B. Yang, J. Zhang, B. Pan, J. Gao, Z. Wang, Clin. Transl. Med. 2021, 11, e288.

[41] J. Xiong, R. Xiao, J. Zhao, Q. Zhao, M. Luo, F. Li, W. Zhang, M. Wu, J. Transl. Med. 2024, 22, 85.

[42] P. Kesarwani, S. Kant, Y. Zhao, A. Prabhu, K. L. Buelow, C. R. Miller, P. Chinnaiyan, Nat. Commun. 2023, 14, 1459.

[43] S. Mafi, B. Mansoori, S. Taeb, H. Sadeghi, R. Abbasi, W. C. Cho, D. Rostamzadeh, Front. Immunol. 2022, 12, 774103.

[44] M. Tsoumakidou, Nat. Rev. Cancer 2023, 23, 258.

[45] D. Briukhovetska, J. Dörr, S. Endres, P. Libby, C. A. Dinarello, S. Kobold, Nat. Rev. Cancer 2021, 21, 481.

[46] W. S. Yang, K. J. Kim, M. M. Gaschler, M. Patel, M. S. Shchepinov, B. R. Stockwell, Proc. Natl. Acad. Sci. USA 2016, 113, E4966.

[47] Q. Shi, C. Xue, Y. Zeng, X. Yuan, Q. Chu, S. Jiang, J. Wang, Y. Zhang, D. Zhu, L. Li, Signal Transduct. Target. Ther. 2024, 9, 128.

[48] A. Mantovani, P. Allavena, F. Marchesi, C. Garlanda, Nat. Rev. Drug Discov. 2022, 21, 799.

[49] W. C. Chou, S. Jha, M. W. Linhoff, J. P. Y. Ting, Nat. Rev. Immunol. 2023, 23, 635.

[50] B. Emir, S. Vranic, A. Sominanda, Carcinogenesis 2024, 46, bgae079.

[51] M. Miao, X. Wang, T. Liu, Y. J. Li, W. Q. Yu, T. M. Yang, S. D. Guo, Int. J. Biol. Macromol. 2023, 242, 125008.

[52] X. Zhao, S. Wei, Z. Li, C. Lin, Z. Zhu, D. Sun, R. Bai, J. Qian, X. Gao, G. Chen, Z. Xu, Cell Death Dis. 2019, 10, 127.

[53] S. Jaiswal, C. H. M. Jamieson, W. W. Pang, C. Y. Park, M. P. Chao, R. Majeti, D. Traver, N. van Rooijen, I. L. Weissman, Cell 2009, 138, 271.

RIGHTS & PERMISSIONS

2026 The Author(s). Interdisciplinary Medicine published by Wiley-VCH GmbH on behalf of Nanfang Hospital, Southern Medical University.